| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.COI.2007.09.004 |
| P698 | PubMed publication ID | 18032008 |
| P2093 | author name string | Raphael Clynes | |
| P2860 | cites work | Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity | Q30835165 |
| P433 | issue | 6 | |
| P304 | page(s) | 646-651 | |
| P577 | publication date | 2007-11-26 | |
| P1433 | published in | Current Opinion in Immunology | Q15752917 |
| P1476 | title | Protective mechanisms of IVIG. | |
| P478 | volume | 19 |
| Q37756017 | A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. |
| Q64262117 | A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity |
| Q37676032 | Advances in diagnosing and managing antibody-mediated rejection |
| Q46038519 | Antibodies: basic mechanisms and emerging concepts. |
| Q50895051 | Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis). |
| Q26830128 | Communication in the heart: the role of the innate immune system in coordinating cellular responses to ischemic injury |
| Q26825801 | Cross-presentation of IgG-containing immune complexes |
| Q39849502 | Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies |
| Q47550160 | Effects of Acyclovir and IVIG on Behavioral Outcomes after HSV1 CNS Infection. |
| Q47220975 | Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease |
| Q33402880 | Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice |
| Q50282049 | High-dose of intravenous immunoglobulin modulates immune tolerance in premature infants. |
| Q37383963 | How B cells shape the immune response against Mycobacterium tuberculosis |
| Q37018736 | Identification of a receptor required for the anti-inflammatory activity of IVIG. |
| Q37502056 | Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. |
| Q36979273 | Immunoglobulin replacement therapy in children |
| Q33401630 | Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia |
| Q36302368 | Intravenous immunoglobulin in the management of lupus nephritis. |
| Q24629268 | Mechanisms involved in antibody- and complement-mediated allograft rejection |
| Q39588670 | Monomeric and dimeric IgG fractions show differential reactivity against pathogen-derived antigens |
| Q43069832 | Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction |
| Q37256467 | Natural antibody contributes to host defense against an attenuated Brucella abortus virB mutant. |
| Q90438756 | Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans |
| Q41173378 | New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins |
| Q33926907 | Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis |
| Q37616061 | Role of IgA and IgA fc receptors in inflammation |
| Q38329556 | Role of innate and adaptive immune mechanisms in cardiac injury and repair |
| Q33758483 | Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice. |
| Q38724772 | The Emerging Importance of IgG Fab Glycosylation in Immunity. |
| Q37091308 | The case for immunomodulatory approaches in treating HSV encephalitis |
| Q35039807 | The role of B cells and humoral immunity in Mycobacterium tuberculosis infection |
| Q86299842 | The role of B cells and humoral immunity in Mycobacterium tuberculosis infection |
| Q38255786 | Three major uncertainties in the antibody therapy of cancer |
| Q33409413 | Tpl2 kinase regulates FcγR signaling and immune thrombocytopenia in mice |
| Q30659434 | Use of Fc-Engineered Antibodies as Clearing Agents to Increase Contrast During PET. |
Search more.